Comparative Pharmacology
Head-to-head clinical analysis: PREMASOL 10 IN PLASTIC CONTAINER versus TRAVASOL 5 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PREMASOL 10 IN PLASTIC CONTAINER versus TRAVASOL 5 5 IN PLASTIC CONTAINER.
PREMASOL 10% IN PLASTIC CONTAINER vs TRAVASOL 5.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential amino acids for protein synthesis and maintenance of nitrogen balance.
Travasol 5.5% is a crystalline amino acid solution that provides essential and nonessential amino acids for protein synthesis, maintaining nitrogen balance, and supporting metabolic functions in parenteral nutrition.
1-2 g/kg/day intravenously as a continuous infusion or in divided doses; typical starting dose for adults with normal renal function: 1 g/kg/day.
500 mL of 5.5% amino acid solution intravenously over 2-4 hours daily, titrated to nitrogen balance and metabolic tolerance.
None Documented
None Documented
The terminal elimination half-life of infused amino acids is approximately 0.5-1 hour for most amino acids, reflecting rapid metabolism and distribution. Clinically, this supports continuous infusion to maintain plasma amino acid levels.
Not applicable as individual amino acids have variable half-lives (minutes to hours). TRAVASOL is a mixture; the clinical context is continuous infusion to maintain plasma levels.
Amino acids in Premasol 10% are metabolized and the nitrogen is eliminated primarily as urea via renal excretion (80-90%). A small fraction is excreted in feces (5-10%) and as ammonia in urine. Biliary excretion is negligible.
Amino acids in TRAVASOL 5.5% are metabolized and nitrogen waste is excreted primarily via renal elimination (as urea, >90% of nitrogen). Fecal elimination is negligible (<2%).
Category C
Category C
Amino Acid Solution
Amino Acid Solution